2024년 9월 10일 16:11

MRM Health Appoints Grégoire Franoux as Chief Business Officer and Adds Ron Robison to its Board of Directors

MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced the appointment of Grégoire Franoux, M.B.A., to the newly created role of Chief Business Off...

2024년 5월 16일 10:03

MRM Health to Present Positive Clinical Data from MH002 in Ulcerative Colitis at Digestive Disease Week (DDW)

MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced it will present positive data for its lead asset, MH002, a live microbial consortium therapy...

2024년 2월 21일 09:30

MRM Health Initiates Clinical Research in Parkinson’s Disease

MRM Health, a clinical-stage biopharmaceutical company, announced today that it has received regulatory and ethics committee approval to start an observational, cross-sectional clinical trial to study the role of the small intestinal microbiome in...

2024년 2월 21일 09:30

MRM 헬스, 파킨슨병 임상 연구 시작

임상 단계의 바이오 제약회사인 MRM 헬스(MRM Health)가 파킨슨병(Parkinson’s Disease, PD)에서 소장 미생물 군집의 역할을 연구하고 소장액과 혈액에서 PD 특이 미생물 및 대사체 지문(microbial and metabolic fingerprint)을 식별하는 관찰성 단면 임상시험을 시...

2023년 6월 7일 16:20

MRM Health Appoints Katja Conrath as Chief Scientific Officer

MRM Health - a clinical-stage biopharmaceutical company focused on developing innovative microbiome-based biotherapeutics based on its proprietary and unique CORAL® platform technology - today announced that it appointed Katja Conrath, PhD, as Chi...

2023년 3월 7일 17:24

MRM Health Completes Patient Recruitment in Ulcerative Colitis Study, Secures Financing and Provides Outlook for 2023

MRM Health—a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics based on its proprietary and unique CORAL® platform technology - today provided a business update on its different o...

2022년 12월 13일 17:14

MRM Health and IFF Reach Second Milestone in the Partnered Type 2 Diabetes Program

MRM Health—a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics—today announced that its Type-2 Diabetes Program, developed in collaboration with IFF (NYSE: IFF) has achieved precl...

2022년 6월 30일 10:55

MRM Health Starts Clinical Trial with Next-Generation Optimized Consortium Therapeutic MH002 in Pouchitis

MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced today that they have received regulatory approval from the Federal Agency for Medicines and Health Products (FAMHP)...